Weight Loss from Cancer Treatment
Discover advice on how to put weight back on following cancer treatment from Taking Cancer On Through Flavour
Search
New cancer therapeutics collaboration with 3T Bio
Boehringer Ingelheim and 3T Biosciences collaborate to discover and develop next-generation cancer therapies to address high unmet patient needs
Big Little Things in cancer: small things, big impacts
Little things can be a big deal when you are living with or treating cancer. Sometimes the small things are the most powerful.
Zongertinib positive results non-small cell lung cancer
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Taking cancer on together
Through their work, our colleagues from around the world hope to empower patients to Take Cancer On.
Our Partners_ViraTherapeutics
Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Strategic-collaboration-with-EnaraBio
Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
Research & Development
Research & Development
Partnership for first-in-class cancer and CRM treatments
Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
Taking Cancer on at Diagnosis
We spoke to Markus, Brigitte and Dr Hochmair who shared their advice for people starting their own cancer journeys.
BI Focuses COVID-19 Clinical Research on Alteplase
BI focuses its COVID-19 therapy research on the development of alteplase as a potential treatment for COVID-19 patients with severe breathing problems
A passion for research which addresses unmet medical needs
Eric Haaksma, Head of Global Innovation Animal Health, explains why his professional purpose is rooted in helping drive advancements in scientific research
Human Pharma Research & Development Approach
Human Pharma Research & Development Approach
Boehringer acquires T3 Pharma
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Dedifferentiated liposarcoma (DDLPS)
An aggressive subtype of a category of cancers called soft tissue sarcoma (STS). DDLPS has a poor prognosis and limited treatment options.
Agreement-to-acquire-Labor-Dr.-Merk
Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
Win Fight Against Cancer
At Boehringer Ingelheim we are giving patients new hope. We are collaborating with the oncology community on a shared journey to deliver leading science.
Data Science
Revolutionizing research and development with data driven insights
Oncology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Inauguration of new integrated Asian Veterinary R&D Center in China
Boehringer Ingelheim confirms its commitment to growth in China with the investment of 19 million euros in its new integrated Asian Veterinary Research & Development Center
Are combination therapies the answer to battling KRAS cancers?
Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal
Striving to revolutionize mental health research
World Mental Health Day: Through a precision psychiatry approach and rich pipeline, we are committed to transforming the mental health landscape.
Boehringer Ingelheim 2022 half year results
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
2018 Animal Welfare Medals
2018 Animal Welfare Medals: Boehringer Ingelheim recognizes outstanding research in cattle, equine, swine, as well as small animals and pet categories
Veganism
Hear an expert’s opinion on the proposed link between a vegan diet and cancer recurrence rates.